Pharmacotherapy for social anxiety disorder (SAnD)

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2017, Pages

  Williams, Taryn ^a   Hattingh, Coenraad J ^a   Kariuki, Catherine M ^a   Tromp, Sean A ^b   van Balkom, Anton J ^c   Ipser, Jonathan C ^a   Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ATENOLOL; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; BROMAZEPAM; BUSPIRONE; CITALOPRAM; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LEVETIRACETAM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; PHENELZINE; PLACEBO; PREGABALIN; QUETIAPINE; SEROTONIN 1A AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; VENLAFAXINE; ANTICONVULSIVE AGENT;

ADULT; ANXIETY; BECK DEPRESSION INVENTORY; BEDTIME DOSAGE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LIEBOWITZ SOCIAL ANXIETY SCALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; MUSCLE SPASM; MYALGIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PAINFUL ERECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE RISK; REMISSION; REVIEW; SEDATION; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SLEEP DISORDER; SOCIAL DISABILITY; SOCIAL PHOBIA; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WORK DISABILITY; AGED; CHRONIC DISEASE; META ANALYSIS; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTICONVULSANTS; CHRONIC DISEASE; HUMANS; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PHOBIA, SOCIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; VENLAFAXINE HYDROCHLORIDE; YOUNG ADULT;

EID: 85032856752     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001206.pub3     Document Type: Review

References (270)

1. Allgulander C. Efficacy of paroxetine in social phobia - a single-center double-blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20-50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4. Paris, France, 1998:P.3.005. 6862318
2. Allgulander C. Paroxetine in social anxiety disorder: a randomised placebo-controlled study. Acta Psychiatrica Scandinavica 1999;100(3):193-8. 3148939
3. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjödin I, Emilien G. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Human Psychopharmacology 2004;19(6):387-96. 6862319
4. Mangano R, Liebowitz MR, Allgulander C. Comparison of venlafaxine extended release and paroxetine in short-term treatment of SAD. New Research Abstracts. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22. San Francisco (CA), 2003. 6862320
5. Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology 2007;10(2):263-74. 6862321
6. 29060/502. Randomised, double-blind study of paroxetine and placebo in the treatment of social phobia. www.gsk-clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). 3148947
7. Baldwin D, Bobes J, Stein DJ, Scharwaechter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. British Journal of Psychiatry 1999;175(2):120-6. 3148946
8. Stein DJ, Berk M, Els C, Emsley RA, Gittelson L, Wilson D, et al. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal 1999;89(4):402-6. 3148948
9. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology 2002;16(4):365-8. 3148950
10. Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry 2010;67(3):286-95. 3148952
11. Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry 2001;179(1):23-30. 3148954
12. Blomhoff S, Haug TT, Humble M, Hallstrom K, Madsbu HP, Wold JE, et al. Treatment of generalized social phobia. New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15-20. Washington DC, 1999:NR650. 3148955
13. Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. British Journal of Psychiatry 2003;182(4):312-8. 3148956
14. Walker JR. The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia. Evidence-based Mental Health 2003;6(3):90. 3148957
15. Book SW, Thomas SE, Randall PK, Randall CL. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. Journal of Anxiety Disorders 2008;22(2):310-8. 3148959
16. Thomas SE, Randall PK, Book SW, Randall CL. A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research 2008;32(1):77-84. 3148960
17. Connor KM, Davidson JR, Potts NL, Tupler LA, Miner CM, Malik ML, et al. Discontinuation of clonazepam in the treatment of social phobia. Journal of Clinical Psychopharmacology 1998;18(5):373-8. 3148962
18. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology 1993;13(6):423-8. 3148964
19. Sutherland SM, Tupler LA, Colket JT, Davidson JR. A 2-year follow-up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease 1996;184(12):731-8. 3148965
20. Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato LM, Van der Hoop RG, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 2004;24(2):118-25. 3148967
21. Davidson JR, Hemby LW, Barbato L, Van der Hoop RG. Fluvoxamine controlled release for the treatment of generalized social anxiety disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10-14;. San Juan, Puerto Rico, 2000:161. 3148968
22. Aderka IM, McLean CP, Huppert JD, Davidson JRT, Foa EB. Fear, avoidance and physiological symptoms during cognitive-behavioral therapy for social anxiety disorder. Behaviour Research and Therapy 2013;51(7):352-8. 3148970
23. Davidson JRT, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry 2004;61(10):1005-13. 3148971
24. Huppert JD, Schultz LT, Foa EB, Barlow DH, Davidson JR, Gorman JM, et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. American Journal of Psychiatry 2004;161(8):1485-7. 3148972
25. Ledley DR, Huppert JD, Foa EB, Davidson JRT, Keefe FJ, Potts NLS. Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depression and Anxiety 2005;22(4):161-7. 3148973
26. Fahlen T, Humble M, Koczkas C, Nilsson H. Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology 1992;15(1 Pt B):64. 3148975
27. Fahlen T, Nilsson Hl, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatrica Scandinavica 1995;92(5):351-8. 3148976
28. Feltner D, Bielski R, Liu-Dumaw M. Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo-controlled, fixed-dose study. European Neuropsychopharmacology 2010;20(Suppl 3):S525-6. 3148978
29. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. International Clinical Psychopharmacology 2011;26(4):213-20. 3148979
30. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram or placebo. Biological Psychiatry 2005;58(2):132-42. 3148981
31. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry 1998;55(12):1133-41. 3148993
32. Kasper S, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder. XII World Congress of Psychiatry; Aug 24-9. Yokohama, Japan, 2002. 3148995
33. Kasper S, Loft H, Smith JR. Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. New Research Abstracts. 155th Annual Meeting of the American Psychiatric Association; May 18-23;. Philadelphia (PA), 2002. 3148996
34. Kasper S, Stein DJ, Loft H, Nil, R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. British Journal of Psychiatry 2005;186(3):222-6. 3148997
35. Katschnig K, Stein MB, Buller R. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience 1997;247(2):71-80. 3148999
36. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. American Journal of Psychiatry 1995;152(9):1368-71. 3149001
37. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. Journal of Clinical Psychopharmacology 2002;22(3):257-62. 3149003
38. Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed dose study. Depression and Anxiety 2004;19:241-8. 3149005
39. Lepola U, Bergtholdt B, Lambert JS, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry 2004;65:222-9. 3149007
40. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, et al. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry 1988;49(7):252-7. 3149009
41. Liebowitz MR, Schneier F, Campeas R, Gorman J, Fyer A, Hollander E, et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin 1990;26(1):123-5. 3149010
42. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Archives of General Psychiatry 1992;49(4):290-300. 3149011
43. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry 2002;63(1):66-74. 3149013
44. Liebowitz MR, DeMartinis NA, Weihs KL, Londborg PD, Smith WT, Chung H, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2003;64(7):785-92. 3149015
45. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Journal of Clinical Psychiatry 2005;66(2):238-47. 3149017
46. Liebow3149018itz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry 2005;62(2):190-8. 6862323
47. Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. Journal of Clinical Psychopharmacology 1997;17(4):255-60. 3149021
48. Moghadam MNM, Atef-Vahid MK, Asgharnejad-Farid AA, Shabani A, Lavasni F. Effectiveness of short-term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences 2015;9(2):e228. 3149023
49. Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Gil FP, et al. Mirtazapine treatment of social phobia in women. A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2005;25(6):580-3. 3149025
50. NCT00273039. A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder [A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/record/NCT00273039 (first received 5 January 2006). 3148983
51. NCT00318669. Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- [Social Anxiety Disorder Study Of Paroxetine]. clinicaltrials.gov/ct2/show/NCT00318669 (first received 24 April 2006). 3148985
52. NCT00397722. Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). 3148989
53. NCT00403962. A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD) [A Combination Therapy In Patients With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT00403962 (first received 29 August 2005). 3148987
54. NCT00470483. A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects With Social Anxiety Disorder [A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/results/NCT00470483 (first received 3 May 2007). 3148991
55. Nordahl HM, Vogel PA, Morken G, Stiles TC, Sandvik P, et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics 2016;85(6):346-56. 6862325
56. Noyes R Jr, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, et al. Moclobemide in social phobia: a controlled dose response trial. Journal of Clinical Psychopharmacology 1997;17(4):247-54. 3149027
57. Oosterbaan DB, Van Balkom AJLM, Spinhoven P, van Oppen P, van Dyck R. Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy 2001;8(4):263-73. 3149029
58. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM. Treatment of social phobia with gabapentin: a placebo-controlled study. Journal of Clinical Psychopharmacology 1999;19(4):341-8. 3149031
59. Feltner DE, Davidson JR, Pollack MH, Stein MB, Futterer R, Jefferson JW, et al. A placebo-controlled, double-blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10-14. San Juan, Puerto Rico, 2000. 3149033
60. Feltner DE, Pollack MH, Davidson JR, Stein MB, Futterer R, Jefferson JW, et al. A placebo-controlled study of pregabalin in social phobia (social anxiety disorder) [abstract]. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):284. 3149034
61. Feltner DE, Pollack MH, Davidson JR, Stein MB, Futterer RA, Jefferson JW, et al. Pregabalin treatment of social phobia. New Research Abstracts. 153rd Annual Meeting of the American Psychiatric Association; May 13-18. Chicago (IL), 2000. 3149035
62. Feltner DE, Pollack MH, Davidson JRT, Stein MB, Futterer R, Jefferson JW, et al. A placebo-controlled, double-blind study of pregabalin treatment of social phobia: outcome and predictors of response [abstract]. European Neuropsychopharmacology 2000;10(Suppl 3):S345. 3149036
63. Pande AC, Feltner DE, Jefferson JW, Davidson JRT, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. Journal of Clinical Psychopharmacology 2004;24(2):141-9. 3149037
64. Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depression & Anxiety 2001;14(4):255-62. 3149039
65. Randall CL, Johnson MR, Thevos AK, Sonne SC, Willard SL, Thomas SE, et al. Paroxetine improves both social anxiety and alcohol use in dual-diagnosed patients. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. 3149040
66. Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. Journal of Clinical Psychopharmacology 2009;29(6):561-4. 3149042
67. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology 2004;24(5):488-96. 3149044
68. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. British Journal of Psychiatry 1998;172:70-7. 3149046
69. Schutters SIJ, Van Megen HJGM, Van Veen JF, Denys DAJP, Westenberg HGM. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. International Clinical Psychopharmacology 2010;25(5):302-4. 3149048
70. Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Coté D, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. Journal of Clinical Psychopharmacology 1996;16(3):218-22. 3149050
71. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280(8):708-13. 3149052
72. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. American Journal of Psychiatry 1999;156(5):756-60. 3149054
73. Stein DJ, Cameron A, Amrein R, Montgomery SA. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology 2002;17(4):161-70. 3149056
74. 29060/595. A study of the maintained efficacy and safety of paroxetine versus placebo in the long-term treatment of social phobia. www.gsk-clinicalstudyregister.com/study/29060/595#rs (first received 28 September 2008). 3149058
75. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Archives of General Psychiatry 2002;59(12):1111-8. 3149059
76. Stein DJ, Westenberg HGM, Yang H, Li D, Barbato LM. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. International Journal of Neuropsychopharmacology 2003;6(4):317-23. 3149061
77. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology 2005;177(3):280-8. 3149063
78. Stein MB, Pollack MH, Mangano R. Long-term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17-22. San Francisco (CA), 2003:NR251. 3149064
79. Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, et al. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. Journal of Clinical Psychiatry 2010;71(5):627-31. 3149066
80. Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology 2010;20(2):80-7. 3149068
81. Turner S, Beidel DC, Jacob RG. Social phobia: a comparison of behaviour therapy and atenolol. Journal of Consulting and Clinical Psychology 1994;62(2):350-8. 3149070
82. Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JRT. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007;31(7):1464-9. 3149072
83. Lane R, Walker J, Swinson R, Van Ameringen M. Sertraline in generalised social phobia. 11th World Congress of Psychiatry; Aug 6-11. Hamburg, Germany, 1999. 3149074
84. Pieters G. Sertraline was effective and well tolerated for generalised social phobia. Evidence-based Mental Health 2001;4(3):91. 3149075
85. Van Ameringen M, Oakman JM, Farvolden PG, Mancini C, Walker JR, Lane RM. Predictors of sertraline response in social phobia. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10-14. San Juan, Puerto Rico, 2000:163. 3149076
86. Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, et al. Sertraline treatment of generalised social phobia: a 20-week, double-blind, placebo-controlled study. American Journal of Psychiatry 2001;158(2):275-81. 3149077
87. Van Ameringen MA, Swinson R, Walker JR, Lane RM. A placebo-controlled study of sertraline in generalized social phobia [abstract]. European Neuropsychopharmacology 2000;10(Suppl 3):S335. 3149078
88. Van Ameringen M, Mancini C, Oakman J, Walker J, Kjernisted K, Chokka P, et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 2007;68(2):288-95. 3149080
89. Van Ameringen MA, Mancini CL, Pipe B, Oakman J, Walker JR, Kjernisted KD, et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo-controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17-22. San Francisco (CA), 2003:NR789. 3149081
90. Van Vliet IM, Den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. European Neuropsychopharmacology 1992;2(1):21-9. 3149083
91. Van Vliet IM, Den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994;115(1-2):128-34. 3149085
92. Van Vliet I, Den Boer J, Westenberg H, Ho Pian K. Clinical effects of buspirone in social phobia, a double-blind placebo controlled study. 9th European College of Neuropsychopharmacology Congress; Sept 21-25. Amsterdam, Netherlands, 1996. 3149087
93. Van Vliet IM, Den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. Journal of Clinical Psychiatry 1997;58(4):164-8. 3149088
94. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry 1992;161:353-60. 3149090
95. Versiani M, Nardi AE, Figueira I, Mendlowicz M, Marques C. Double-blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria 1997;46(3):167-71. 3149092
96. Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology 2000;20(6):636-44. 3149094
97. Walker JR, Van Ameringen MA, Swinson RP, Lane RM. A 24-week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13-18. Chicago (IL), 2000:NR259. 3149095
98. Westenberg HGM, Stein DJ, Yang H, Li D, Barbato LM. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 2004;24(1):49-55. 3149097
99. Zhang W, Connor KM, Davidson JRT. Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology 2005;19(5):551-3. 3149099
100. ACTRN12608000363381. Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants [Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants]. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12608000363381 (first received 9 July 2008). 6862327
101. ACTRN12609000091202. The use of tiagabine and gabapentin in the treatment of social anxiety disorder in 8 patients [Gabapentin and tiagabine for treatment of social anxiety disorder in 8 patients in a random double blind crossover study with outcome measured as changes in the Leibowitz Social Anxiety Scale]. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12609000091202 (first received 18 December 2008). 6862329
102. Allsopp LF, Cooper GL, Poole PH. Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Current Medical Research and Opinion 1984;9(1):64-70. 3149101
103. Angelini G, Bichisao E, Catapano F, Cerreta A, Ferini Strambi L, Maj M, et al. Ketazolam, a new long-acting benzodiazepine, in the treatment of anxious patients. A multicenter study of 2, 056 patients. Current Therapeutic Research, Clinical and Experimental 1989;45(2):294-304. 3149103
104. Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Human Psychopharmacology 2002;2002(8):401-5. 3149105
105. Blank S, Lenze EJ, Mulsant BH, Dew MA, Karp JF, Shear MK, et al. Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. Journal of Clinical Psychiatry 2006;67(3):468-72. 3149107
106. Brantigan CO, Brantigan TA, Joseph N. Effects of beta-blockade and beta-stimulation on stage fright. American Journal of Medicine 1982;72(1):88-94. 3149109
107. Bystritsky A, Kerwin L, Eiduson S, Vapnik T. A pilot controlled trial of bupropion vs. escitalopram in generalized anxiety disorder (GAD). Neuropsychopharmacology 2005;30 Suppl(1):S101. 3149111
108. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. Journal of Consulting and Clinical Psychology 2003;71(6):1058-67. 3149113
109. Clark-Elford R, Nathan PJ, Auyeung B, Mogg K, Bradley, BP, Sule A, et al. Effects of oxytocin on attention to emotional faces in healthy volunteers and highly socially anxious males. International Journal of Neuropsychopharmacology 2014;18(2):1-7. 3149115
110. Coupland NJ, Bell C, Potokar JP, Dorkins E, Nutt DJ. Flumazenil challenge in social phobia. Depression and Anxiety 2000;11(1):27-30. 3149117
111. Dempsey JP, Randall PK, Thomas SE, Book SW, Carrigan MH. Treatment of social anxiety with paroxetine: mediation of changes in anxiety and depression symptoms. Comprehensive Psychiatry 2009;50(2):135-41. 3149119
112. Dodhia S, Hosanagar A, Fitzgerald DA, Labuschagne I, Wood AG, Nathan PJ, et al. Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder. Neuropsychopharmacology 2014;39(9):2061-9. 3149121
113. Donahue CB, Kushner MG, Thuras PD, Murphy TG, Van Demark JB, Adson DE. Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. Journal of Anxiety Disorders 2009;23(3):362-8. 3149123
114. Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT. Tiagabine for social anxiety disorder. Human Psychopharmacology: Clinical and Experimental 2007;22(4):241-4. 3149125
115. EUCTR2004-001894-24-DE. A randomised, double-blind, parallel-group, placebo-controlled fixed dose study comparing the efficacy and safety of GW597599/paroxetine combination or paroxetine monotherapy to placebo in patients with social anxiety disorder (SAD). apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2004-001894-24-DE 2012. 6862331
116. Falloon IR, Llody GG, Harpin RE. The treatment of social phobia: real-life rehearsal with nonprofessional therapists. Journal of Nervous and Mental Disease 1981;169(3):180-4. 3149127
117. Fang A, Hoge EA, Heinrichs M, Hofmann SG. Attachment style moderates the effects of oxytocin on social behaviors and cognitions during social rejection: applying a research domain criteria framework to social anxiety. Clinical Psychological Science 2014;2(6):740-7. 3149129
118. Faria V, Ahs F, Appel L, Linnman C, Bani M, Bettica P, et al. Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder. International Journal of Neuropsychopharmacology 2014;17(8):1149-57. 3149133
119. Feifel D, Macdonald K, McKinney R, Heissere N, Serrano V. A randomized, placebo controlled investigation of intranasal oxytocin in patients with anxiety. Neuropsychopharmacology 2011;36:S421. 3149135
120. Gale C. Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder. Evidence Based Mental Health 2007;10(2):45. 3149137
121. Gates GA, Saegert J, Wilson N, Johnson L, Shepherd A, Hearne EM 3rd. Effect of beta-blockage on singing performance. Annals of Otology, Rhinology and Laryngology 1985;94(6 Pt 1):570-4. 3149139
122. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, et al. Cognitive-behavioural and pharmacological treatments of social phobia: a controlled study. Archives of General Psychiatry 1991;48(10):938-45. 3149141
123. Gorka SM, Fitzgerald DA, Labuschagne I, Hosanagar A, Wood AG, Nathan PJ, et al. Oxytocin modulation of amygdala functional connectivity to fearful faces in generalized social anxiety disorder. Neuropsychopharmacology 2015;40(2):278-86. [3149145]6862332
124. Greenhill LL. A multisite treatment of anxiety disorders. 152nd Annual Meeting of the American Psychiatric Association; May 15-20;. Washington DC, 1999. 3149147
125. Grosser B, Monti-Bloch L, Jennings-White C. Rapid anti-anxiety effects in women of picogram quantities of a 19-carbon steroid [abstract]. International Journal of Neuropsychopharmacology 2012:230-1. 3149149
126. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009;34(6):917-23. 3149151
127. Hartley LR, Ungapen S, Davie I, Spencer DJ. The effect of beta adrenergic blockade on speaker's performance and memory. British Journal of Psychiatry 1983;142(5):512-7. 3149153
128. Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Exposure therapy and sertraline in social phobia: 1-year follow up of a randomised controlled trial. British Journal of Psychiatry 2003;182:312-8. 3149155
129. Heun R, Corral RM, Ahokas A, Nicolini H, Teixeira JM, Dehelean P. Efficacy of agomelatine in more anxious elderly depressed patients. A randomized, double-blind study vs placebo. European Psychiatry 2013;28(Suppl 1):1. 3149157
130. Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Archives of General Psychiatry 2006;63(3):298-304. 3149159
131. Ionescu D. Clinical study on the efficacy and tolerability of escitalopram in patients diagnosed with social anxiety [abstract]. European Psychiatry 2013;28(1):1. 3149161
132. James IM, Griffith DN, Pearson RM, Newbury P. Effect of oxprenolol on stage-fright in musicians. Lancet 1977;2(8045):952-4. 3149163
133. James IM, Burgoyne W, Savage IT. Effect on pindolol on stress-related disturbances of musical performance: preliminary communication. Journal of the Royal Society of Medicine 1983;76(3):194-6. 3149165
134. James I, Savage I. Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo. American Heart Journal 1984;108(4 Pt 2):1150-5. 3149167
135. Krishman G. Oxprenolol in the treatment of examination stress. Current Medical Research and Opinion 1976;4(3):241-3. 3149169
136. Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazepine administration. Journal of Affective Disorders 2003;76(1-3):279-84. 3149171
137. Liden S, Gottfries CG. Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians. Lancet 1974;2(7879):529. 3149173
138. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depression and Anxiety 1999;10(3):89-98. 3149175
139. Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L. Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder. American Journal of Psychiatry 2014;171(6):675-82. 3149177
140. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcoholism Clinical and Experimental Research 1992;16(6):1007-13. 3149179
141. Mangano R, Liebowitz MR, Allgulander C. Comparison of venlafaxine extended release and paroxetine in short-term treatment of SAD. 156th Annual Meeting of the American Psychiatric Association, May 17-22. San Francisco (CA), 2003. 3149181
142. Mortberg E, Clark DM, Sundin O, Aberg Wistedt A. Intensive group cognitive treatment and individual cognitive therapy vs treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatrica Scandinavica 2007;115(2):142-54. 3149183
143. Mountjoy CQ, Roth M, Garside RF, Leitch IM. A clinical trial of phenelzine in anxiety depressive and phobic neuroses. British Journal of Psychiatry 1977;131:486-92. 3149185
144. NCT00118833. St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD) [Placebo-Controlled Trial of Hypericum Perforatum in the Treatment of Generalized Social Anxiety Disorder (GSAD)]. clinicaltrials.gov/ct2/show/NCT00118833 (first received 7 July 2005). 3149233
145. NCT00248612. Psychosocial and Medication Treatment for Anxiety in Alcoholism. clinicaltrials.gov/ct2/show/results/NCT00248612 (first received 2 November 2005). 3149131
146. NCT00308724. Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care. clinicaltrials.gov/ct2/show/NCT00308724 (first received 28 March 2006). 3149225
147. NCT00332046. fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder [A Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Parallel Group, fMRI Study Comparing BOLD Activation Patterns Before and After 12 Weeks of Treatment With Placebo, Comparator and GW679769 in Subjects With Social Anxiety Disorder (SAD)]. clinicaltrials.gov/ct2/show/NCT00332046 (first received 30 May 2006). 3149187
148. NCT00343707. PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients [A Double-blind, Triple Dummy, Placebo-controlled, Randomised, Parallel Group Positron Emission Tomography Study to Investigate the Effects of a 8 Week Administration of GW597599 and Paroxetine Either Alone or in Combination on Regional Cerebral Blood Flow During a Public Speaking Test in Subjects Affected by Social Phobia]. clinicaltrials.gov/ct2/show/NCT00343707 (first received 21 June 2006). 3149143
149. Neftel KA, Adler RH, Kappeli L, Rossi M, Dolder M, Kaser HE, et al. Stage fright in musicians: a model illustrating the effect of beta blockers. Psychosomatic Medicine 1982;44(5):461-9. 3149189
150. Oosterbaan D, Van Balkom A, Spinhoven, Van Dyk R. Cognitive behavior therapy versus moclobemide in social phobia. The World Psychiatric Association's (WPA) Thematic Congress; Nov. Jerusalem, 1997. 3149191
151. Otto MW, Pollack MH, Gould RA, Worthington JJ, McArdle ET, Rosenbaum JF. A comparison of the efficacy of clonazepam and cognitive-behavioural group therapy for the treatment of social phobia. Journal of Anxiety Disorders 2000;14(4):345-8. 3149193
152. Pecknold JC, McClure DJ, Appeltauer L, Allan T, Wrzesinski L. Does tryptophan potentiate clomipramine in the treatment of agoraphobic and agoraphobic and social phobic patients. British Journal of Psychiatry 1982;140:484-90. 3149195
153. Phan KL. Oxytocin modulation of amygdala-frontal reactivity and connectivity to threat and at rest in social anxiety disorder [abstract]. Biological Psychiatry 2015;75(9 Suppl 1):27S. 3149197
154. Pine DS, Walkup JT, Labellarte MJ, Riddle MA, Greenhill L, Klein R, et al. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine 2001;344(17):1279-85. 3149203
155. Prasko J. Moclobemide and/or cognitive-behavior therapy in the treatment of social phobia. 157th Annual Meeting of the American Psychiatric Association; May 1-6. New York (NY), 2004. 3149199
156. Ravindran AV, Abraham G, Johnson S, Chandrasena R. Randomized, placebo-controlled effectiveness study of quetiapine XR in co-morbid depressive and anxiety disorders [abstract]. International Journal of Neuropsychopharmacology 2014;46(1):91. 3149201
157. Rickels K, Case WG, Chung H. Diazepam and halazepam in anxiety: some prognostic indicators. International Pharmacopsychiatry 1978;13(2):118-25. 3149205
158. Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and Anxiety 2008;25(3):182-9. 3149207
159. Schuurmans J, Comijs HC, Emmelkamp PM, Van Dyck R. A randomized controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waiting list control group for anxiety disorders in older adults. 32nd Congress of the British Association for Behavioural and Cognitive Psychotherapies (jointly with the European Association of Behavioural and Cognitive Therapies); Sept 7-11. Manchester, UK, 2004. 3149209
160. Seedat S, Stein M. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. American Journal of Psychiatry 2001;158(10):1725-7. 3149211
161. Shlik J, Maron E, Aluoja A, Vasar V, Toru I. Citalopram challenge in social anxiety disorder. European Neuropsychopharmacology 2002;12(Suppl 3):S339. 3149213
162. Siitonen L, Janne J. Effect of beta-blockade during bowling competition. Annals of Clinical Research 1976;8(6):393-8. 3149215
163. Silverstone JT, Salkind MR. Controlled evaluation of intravenous drugs in the specific desensitization of phobias. Canadian Psychiatric Association Journal 1973;18(1):47-53. 3149217
164. Simon NM, Worthington JJ, Moshier SJ, Marks EH, Hoge EA, Brandes M, et al. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectrums 2010;15(7):436-43. 3149219
165. Solyom L, Heseltine GF, McClure DJ, Solyom C, Ledwidge B, Steinberg G. Behaviour therapy versus drug therapy in the treatment of phobic neurosis. Canadian Psychiatric Association Journal 1973;18(1):25-32. 3149221
166. Solyom C, Solyom L, LaPierre Y, Pecknold J, Morton L. Phenelzine and exposure in the treatment of phobias. Biological Psychiatry 1981;16(3):239-47. 3149223
167. Tubaki BR, Chandrashekar CR, Sudhakar D, Prabha TN, Lavekar GS, Kutty BM. Clinical efficacy of manasamitra vataka (an Ayurveda Medication) on generalized anxiety disorder with comorbid generalized social phobia: a randomized controlled study. Journal of Alternative & Complementary Medicine 2012;18(6):612-21. 3149227
168. Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologica 1973;32(3):237-54. 3149229
169. Wardle MC, Frye CG, De Wit H. MDMA buffers against cues of social rejection [abstract]. Neuropsychopharmacology 2012:S414-5. 3149231
170. Asakura S, Hayano T, Hagino A, Koyama T. A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan. Current Medical Research and Opinion 2016;32(4):749-57. [DOI: 10.1185/03007995.2016.1146663]6862334
171. Careri JM, Draine AE, Hanover R, Liebowitz MR. A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder. The Primary Care Companion for CNS Disorders 2015;17(6):e1-e6. [DOI: 10.4088/PCC.15m01831]6862336
172. De la Barquera JAOS. Double-blind controlled study with clonazepam and placebo in social anxiety disorder. Salud Mental 2008;31(4):299-306. 3149235
173. Frick A, Ahs F, Appel L, Jonasson M, Linnman C, Faria V, et al. Reduced serotonin synthesis after pharmacological treatment of social anxiety disorder [abstract]. Biological Psychiatry 2015;77(9):236. 3149237
174. Krylov V. Pharmacological treatment of social phobia: a controlled study with alprazolam and buspirone. 9th European College of Neuropsychopharmacology (ECNP) Congress. Amsterdam, Netherlands, 1996. 3149241
175. NCT00114127. Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome [Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome]. clinicaltrials.gov/ct2/show/NCT00114127 (first received 13 June 2005). 6862338
176. NCT00208741. Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder [A 12-Week Open-Label Study Followed By A 24-Week Double-Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitril™ (Tiagabine Hydrochloride) In Patients With Social Anxiety Disorder (SAD)]. clinicaltrials.gov/ct2/show/NCT00208741 (first received 13 September 2005). 6862340
177. NCT00215254. Quetiapine in Social Anxiety Disorder [A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quetiapine in Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT00215254 (first received 20 September 2005). 6862342
178. NCT00246441. Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism [Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism]. clinicaltrials.gov/ct2/show/NCT00246441 (first received 28 October 2005). 6862344
179. NCT00294346. Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder [A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT00294346 17 February 2006). 6862346
180. NCT00485888. Flushing in Social Anxiety Disorder on Cipralex [Changes in the Vasodilatory Response to Methyl-nicotinate in Response to S-citalopram Treatment in Social Phobia Patients]. clinicaltrials.gov/ct2/show/NCT00485888 (first received 12 June 2007). 3149239
181. NCT00612859. Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type) [A Multicenter, Randomized, Double-Blind, PBO-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Levetiracetam Versus PBO for the Treatment of Social Anxiety Disorder (Generalized Type)]. clinicaltrials.gov/ct2/show/NCT00612859 (first received 14 January 2008). 6862348
182. NCT01316302. 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder [A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT01316302 (first received 14 March 2011). 6862350
183. NCT00182533. Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders [Sertraline in the Treatment of Generalized Social Phobia With Comorbidity]. clinicaltrials.gov/ct2/show/NCT00182533 (first received 14 September 2005). 3149251
184. NCT01712321. Study of Vilazodone to Treat Social Anxiety Disorder [Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study]. clinicaltrials.gov/ct2/show/NCT01712321 (first received 18 October 2012). 3149247
185. NCT02083926. Ketamine Infusion for Social Anxiety Disorder [Ketamine Infusion for Social Anxiety Disorder]. clinicaltrials.gov/show/NCT02083926 (first received 5 March 2014). 3149243
186. NCT02294305. ortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder. clinicaltrials.gov/show/NCT02294305 (first received 11 November 2014). 3149249
187. NCT02432703. A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder [A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder]. clinicaltrials.gov/show/NCT02432703 (first received 29 April 2015). 3149245
188. Aarre TF. Phenelzine efficacy in refractory social anxiety disorder: a case series. Nordic Journal of Psychiatry 2003;57(4):313-5.
189. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials - a reflection of treatment effect or adverse events?. JAMA 2003;290(7):921-8.
190. Bailar JC 3rd. The promise and problems of meta-analysis. New England Journal of Medicine 1999;337(8):559-61.
191. Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry 2003;183(6):498-506.
192. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, Den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology 2014;28(5):403-39. [DOI: 10.1177/0269881114525674]
193. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, BobesJ, Beidel DC, et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry 1998;59(Suppl 17):54-60.
194. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. WFSBP Task Force on Treatment Guidelines for Anxiety O-CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World Journal of Biological Psychiatry 2002;3(4):171-99.
195. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, et al. WFSBP Task Force on Mental Disorders in Primary Care, WFSBP Task Force on Anxiety Disorders, OCD, PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive - compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice 2012;16:77-84. [DOI: 10.3109/13651501.2012.667114]
196. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience 2015;17(3):327-35.
197. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiartry 1961;4(6):561-71.
198. Blanco C, Antia SX, Liebowitz MR. Pharmacotherapy of social anxiety disorder. Biological Psychiatry 2002;51(1):109-20.
199. Blanco C, Schneier FR, Schmidt A, Blanco-Jerez C, Marshall RD, Sanchez-Lacay A, et al. Pharmalogical treatment of social anxiety disorder: a meta-analysis. Depression and Anxiety 2003;18(1):29-40.
200. Blanco C, Bragdon LB, Schneier FR, Liebowitz MR. The evidence-based pharmacotherapy of social anxiety disorder. International Journal of Neuropsychopharmacology 2013;16(1):235-49.
201. Chamberlain SR, Del Campo N, Dowson J, Müller U, Clark L, Robbins TW, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biological Psychiatry 2007;62(9):977-84.
202. Cowen PJ. Pharmacotherapy for anxiety disorders: drugs available. Advances in Psychiatric Treatment 1997;3:66-71.
203. Curtiss J, Andrews L, Davis M, Smits J, Hofmann SG. A meta-analysis of pharmacotherapy for social anxiety disorder: anexamination of efficacy, moderators, and mediators. Expert Opinion on Pharmacotherapy 2017;18(3):243-51. [hdl.handle.net/2144/21703]
204. Davidson JR, Ford SM, Smith RD, Potts NL. Long-term treatment of social phobia with clonazepam. Journal of Clinical Psychiatry 1991;52(Suppl 1):16-20.
205. Davidson JR. Pharmacotherapy of social anxiety disorder. Journal of Clinical Psychiatry 1998;59(Suppl 17):47-51.
206. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us?. Journal of Clinical Psychiatry 2006;67(Suppl 12):20-6.
207. Davies SJ, Champion C, Dawson S, Sharp J, Churchill R. The Subway Map - a new way to visualize antidepressant classification (a Cochrane CCDAN initiative). 14th ICGP and 19th JSNP Joint Congress; 3 October. Tsukuba, Japan, 2014:78. [Abstract P14]
208. Davis ML, Smits JAJ, Hofmann SG. Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. Expert Opinion on Pharmacotherapy 2014;15(16):2281-91.
209. De Menezes GB, Coutinho ESF, Fontenelle LF, Vigne P, Figueira I, Versiani Má. Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials. Psychopharmacology 2011;215(1):1-11.
210. Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Annals of Internal Medicine 2011;155(1):39-51.
211. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2008:285-312.
212. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2002;21(11):1575-600.
213. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2008:285-312.
214. Dickersin K, Min YI, Meinert CL. Factors influencing the publication of research results: follow-up of applications submitted to two substantial review boards. JAMA 1992;267(3):374-8.
215. Dorrepaal E, Thomaes K, Hoogendoorn AW, Veltman DJ, Draijer N, Van Balkom AJLM. Evidence-based treatment for adult women with child abuse-related Complex PTSD: a quantitative review. European Journal of Psychotraumatology 2014;14(5):236-413.
216. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Press, 1980.
217. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994.
218. Easterbrook PJ, Berline JA, Gopalan R, Mathews DR. Publication bias in clinical research. Lancet 1991;337(8746):867-72.
219. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13(315(7109)):629-34.
220. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
221. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia. Journal of Clinical Psychopharmacology 2001;21(3):311-24.
222. Ford C, Law F. Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and anxiolytics in general practice. www.emcdda.europa.eu/attachements.cfm/att_248926_EN_UK59_benzos (accessed prior to 26 July 2017).
223. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Långström B, et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Archives of General Psychiatry 2002;59(5):425-33.
224. Gorman JM, Gorman LK. Drug treatment of social phobia. Journal of Affective Disorders 1987;13(2):183-92.
225. Gorman JM. Treating generalized anxiety disorder. Journal of Clinical Psychiatry 2003;64(Suppl 2):24-9.
226. Gould RA, Buckminister S, Pollack MH, Otto MW, Yap L. Cognitive-behavioral and pharmacological treatments of social phobia. Clinical Psychology - Science & Practice 1997;4(4):291-306.
227. Gury C, Cousin F. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. Encephale 1999;25(5):470-6.
228. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US National Institute of Health, 1976.
229. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32(1):50-5.
230. Higgins JT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(6):557-60.
231. Higgins JPT, Greens S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.
232. Hubbard CS, Labus JS, Bueller J, Stains J, Suyenobu B, Dukes GE, et al. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional arousal circuit during expectation of abdominal pain. Journal of Neuroscience 2011;31(35):12491-500.
233. Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD005170.pub2]
234. Ipser JC, Sander C, Seifan A, Stein DJ. Augmentation of psychotherapy with d-cycloserine for anxiety disorders. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007803]
235. Irwig L, Macaskill P, Berry G, Glasziou P. Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ 1998;316(7109):470-1.
236. Kelsey JE. Venalafaxine in social phobia. Psychopharmacology Bulletin 1995;31(4):767-71.
237. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Ehsleman S, et al. Lifetime and 12-month prevalence of DSM III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 1994;51(1):8-19.
238. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005;62(6):593-602.
239. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. Journal of Clinical Psychopharmacology 2002;22(3):257-62.
240. Licata SC, Rowlett JK. Abuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyond. Pharmacology Biochemistry & Behavior 2008;90(1):74-89.
241. Liebowitz MR. Social Phobia. Modern Problems in Pharmacopsychiatry 1987;22:141-73.
242. Lumley, T. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002;21(16):2313-24.
243. Marks IM, Gelder MG. Different ages of onset in varieties of phobias. American Journal of Psychiatry 1966;123(2):218-21.
244. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. the Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108(5):1-9.
245. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999;354(9193):1896-900.
246. Mulrow CD, Oxman AD. Cochrane Collaboration Handbook. Oxford: Update Software, 1997.
247. Nemeroff CB, Entsuah R, Benattia I. Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs. Biological Psychiatry 2008;63(4):424-34.
248. National Institute for Health and Care Excellence. Common mental health problems: identification and pathways to care. NICE Clinical Guideline; 2011. Available from www.nice.org.uk.
249. Pecknold JC. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Safety 1997;16(2):118-32.
250. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology 2008;61(10):991-6.
251. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
252. Roest AM, de Jonge P, Williams CD, de Vries YA, Schoevers RA, Turner EH. Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: a report of 2 meta-analyses. JAMA Psychiatry 2015;72(5):500-10. [DOI: doi:10.1001/jamapsychiatry.2015.15]
253. Scherer RW, Dickersin K, Langenberg P. Full publication of results initially presented in abstracts. A meta-analysis. JAMA 1994;272(2):158-62.
254. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. International Clinical Psychopharmacology 1996;11(Suppl 3):89-95.
255. Song F, Altman DG, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326(7387):472.
256. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. Cambridge University Press, 2008.
257. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. American Journal of Psychiatry 2001;158(10):1725-7.
258. Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. Journal of Clinical Psychiatry 2002;63(2):152-5.
259. Stein DJ, Hunter B, Rolfe T, Oakes, R. Paroxetine in social anxiety disorder: a remission analysis. European College of Neuropsychopharmacology (ECNP) Congress; Oct. Barcelona, Spain, 2002.
260. Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD001206.pub2]
261. Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008;271(9618):1115-25.
262. Stahl M, Moore BA. Anxiety Disorders: A Guide for Integrating Psychopharmacology and Psychotherapy (Clinical Topics in Psychology and Psychiatry). 1st edition. Routledge, 2013.
263. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
264. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309(6965):1351-15.
265. Van Ameringen M, Mancini C, Wilson C. Busiprone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. Journal of Affective Disorders 1996;39(2):115-21.
266. Van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. International Clinical Psychopharmacology 2000;15(Suppl 2):15-24.
267. Verbeke M, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer, 2000.
268. Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software 2010;36(3):1-48.
269. Wancata J, Fridl M, Friedrich F. Social phobia: epidemiology and health care. Psychiatrica Danubina 2009;21(4):520-4.
270. Stein DJ, Ipser JC, van Balkom AJ. Pharmacotherapy for social anxiety disorder. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD001206. [DOI: 10.1002/14651858.CD001206.pub2]